---
document_datetime: 2025-12-02 05:07:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vaniqa.html
document_name: vaniqa.html
version: success
processing_time: 0.1063324
conversion_datetime: 2025-12-25 06:27:07.546076
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vaniqa

[RSS](/en/individual-human-medicine.xml/65686)

##### Authorised

This medicine is authorised for use in the European Union

eflornithine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Vaniqa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vaniqa.

Expand section

Collapse section

## What is Vaniqa?

Vaniqa is a white cream that contains the active substance eflornithine (115 mg).

## What is Vaniqa used for?

Vaniqa is used for the treatment of facial hirsutism in women. Facial hirsutism is excessive growth on the face of coarse hair, often in a male pattern.

The medicine can only be obtained with a prescription.

## How is Vaniqa used?

Vaniqa is applied to clean and dry affected areas of the face and under the chin twice a day (at least eight hours apart). It is applied in a thin layer and rubbed in thoroughly.

Improvements may be noticed within eight weeks of starting treatment. Continued treatment is needed to maintain the beneficial effects and may lead to further improvement. Vaniqa should be stopped if no improvements are noticed within four months of starting treatment.

Women using Vaniqa may still need to use other means to remove hair (plucking, shaving).

## How does Vaniqa work?

The active substance in Vaniqa, eflornithine, works by blocking the action of an enzyme called ornithine decarboxylase. This enzyme is found in the bulb of the hair follicle where it controls hair production. When this enzyme is blocked, the growth of hair is slowed down.

## How has Vaniqa been studied?

Vaniqa has been studied in two clinical trials involving 596 women treated for up to 24 weeks with Vaniqa or placebo (a dummy treatment, in this case the cream without any active substance).

The effectiveness of the treatment was assessed at the end of the study by a doctor who graded the hirsutism as 'clear / almost clear', 'marked improvement', 'improved' or 'no improvement / worse', 48 hours after women had shaved the treated areas of the face and under the chin.

## What benefit has Vaniqa shown during the studies?

Improvement was seen as early as eight weeks after starting treatment. In both studies, significant improvement was seen with Vaniqa compared with placebo. When the results were combined, a successful outcome (graded as 'clear / almost clear' or 'marked improvement') was seen in 35% of the women treated with Vaniqa, compared with 9% of those treated with placebo.

## What is the risk associated with Vaniqa?

The most common side effect with Vaniqa (seen in more than 1 patient in 10) is acne. For the full list of all the side effects reported with Vaniqa, see the package leaflet.

Vaniqa should not be used in people who may be hypersensitive (allergic) to eflornithine or any of the other ingredients.

## What measures are being taken to ensure the safe use of Vaniqa?

The CHMP decided that Vaniqa's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Vaniqa

The European Commission granted a marketing authorisation valid throughout the European Union, for Vaniqa on 20 March 2001. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Vaniqa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Vaniqa : EPAR - Summary for the public

Reference Number: EMA/230891/2013

English (EN) (72.8 KB - PDF)

**First published:** 01/09/2008

**Last updated:** 15/04/2013

[View](/en/documents/overview/vaniqa-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-267)

български (BG) (122.13 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/bg/documents/overview/vaniqa-epar-summary-public_bg.pdf)

español (ES) (94.94 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/es/documents/overview/vaniqa-epar-summary-public_es.pdf)

čeština (CS) (119.9 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/cs/documents/overview/vaniqa-epar-summary-public_cs.pdf)

dansk (DA) (94.44 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/da/documents/overview/vaniqa-epar-summary-public_da.pdf)

Deutsch (DE) (95.82 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/de/documents/overview/vaniqa-epar-summary-public_de.pdf)

eesti keel (ET) (88.17 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/et/documents/overview/vaniqa-epar-summary-public_et.pdf)

ελληνικά (EL) (100.14 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/el/documents/overview/vaniqa-epar-summary-public_el.pdf)

français (FR) (96.65 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/fr/documents/overview/vaniqa-epar-summary-public_fr.pdf)

italiano (IT) (94.81 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/it/documents/overview/vaniqa-epar-summary-public_it.pdf)

latviešu valoda (LV) (95.14 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/lv/documents/overview/vaniqa-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (118.37 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/lt/documents/overview/vaniqa-epar-summary-public_lt.pdf)

magyar (HU) (116.05 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/hu/documents/overview/vaniqa-epar-summary-public_hu.pdf)

Malti (MT) (133.81 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/mt/documents/overview/vaniqa-epar-summary-public_mt.pdf)

Nederlands (NL) (96.24 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/nl/documents/overview/vaniqa-epar-summary-public_nl.pdf)

polski (PL) (122.24 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/pl/documents/overview/vaniqa-epar-summary-public_pl.pdf)

português (PT) (95.3 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/pt/documents/overview/vaniqa-epar-summary-public_pt.pdf)

română (RO) (117.85 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/ro/documents/overview/vaniqa-epar-summary-public_ro.pdf)

slovenčina (SK) (120.85 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/sk/documents/overview/vaniqa-epar-summary-public_sk.pdf)

slovenščina (SL) (112.28 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/sl/documents/overview/vaniqa-epar-summary-public_sl.pdf)

Suomi (FI) (94.38 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/fi/documents/overview/vaniqa-epar-summary-public_fi.pdf)

svenska (SV) (95.46 KB - PDF)

**First published:**

01/09/2008

**Last updated:**

15/04/2013

[View](/sv/documents/overview/vaniqa-epar-summary-public_sv.pdf)

## Product information

Vaniqa : EPAR - Product Information

English (EN) (328.37 KB - PDF)

**First published:** 28/09/2009

**Last updated:** 27/11/2024

[View](/en/documents/product-information/vaniqa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-962)

български (BG) (381.1 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/bg/documents/product-information/vaniqa-epar-product-information_bg.pdf)

español (ES) (323.82 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/es/documents/product-information/vaniqa-epar-product-information_es.pdf)

čeština (CS) (373 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/cs/documents/product-information/vaniqa-epar-product-information_cs.pdf)

dansk (DA) (335.19 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/da/documents/product-information/vaniqa-epar-product-information_da.pdf)

Deutsch (DE) (326.76 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/de/documents/product-information/vaniqa-epar-product-information_de.pdf)

eesti keel (ET) (342.96 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/et/documents/product-information/vaniqa-epar-product-information_et.pdf)

ελληνικά (EL) (407.01 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/el/documents/product-information/vaniqa-epar-product-information_el.pdf)

français (FR) (341.36 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/fr/documents/product-information/vaniqa-epar-product-information_fr.pdf)

hrvatski (HR) (354.4 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/hr/documents/product-information/vaniqa-epar-product-information_hr.pdf)

íslenska (IS) (331.39 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/is/documents/product-information/vaniqa-epar-product-information_is.pdf)

italiano (IT) (324.67 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/it/documents/product-information/vaniqa-epar-product-information_it.pdf)

latviešu valoda (LV) (357.36 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/lv/documents/product-information/vaniqa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (375.8 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/lt/documents/product-information/vaniqa-epar-product-information_lt.pdf)

magyar (HU) (394.7 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/hu/documents/product-information/vaniqa-epar-product-information_hu.pdf)

Malti (MT) (375.68 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/mt/documents/product-information/vaniqa-epar-product-information_mt.pdf)

Nederlands (NL) (356.44 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/nl/documents/product-information/vaniqa-epar-product-information_nl.pdf)

norsk (NO) (337.69 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/no/documents/product-information/vaniqa-epar-product-information_no.pdf)

polski (PL) (394.73 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/pl/documents/product-information/vaniqa-epar-product-information_pl.pdf)

português (PT) (324.1 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/pt/documents/product-information/vaniqa-epar-product-information_pt.pdf)

română (RO) (396.11 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/ro/documents/product-information/vaniqa-epar-product-information_ro.pdf)

slovenčina (SK) (374.17 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/sk/documents/product-information/vaniqa-epar-product-information_sk.pdf)

slovenščina (SL) (339.32 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/sl/documents/product-information/vaniqa-epar-product-information_sl.pdf)

Suomi (FI) (324.21 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/fi/documents/product-information/vaniqa-epar-product-information_fi.pdf)

svenska (SV) (320.21 KB - PDF)

**First published:**

28/09/2009

**Last updated:**

27/11/2024

[View](/sv/documents/product-information/vaniqa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0059 29/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vaniqa : EPAR - All Authorised presentations

English (EN) (58.98 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-721)

български (BG) (47.74 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/bg/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_bg.pdf)

español (ES) (58.29 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/es/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (70.32 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/cs/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.69 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/da/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.98 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/de/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (56.19 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/et/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.04 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/el/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_el.pdf)

français (FR) (57.93 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fr/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (329.34 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hr/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (149.46 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/is/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.55 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/it/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (81.79 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lv/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (80.09 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lt/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.85 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hu/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.3 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/mt/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (57.62 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/nl/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (149.29 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/no/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_no.pdf)

polski (PL) (83.2 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pl/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.8 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pt/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.87 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/ro/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.92 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sk/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (66.94 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sl/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (59.67 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fi/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.66 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sv/documents/all-authorised-presentations/vaniqa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vaniqa Active substance eflornithine International non-proprietary name (INN) or common name eflornithine Therapeutic area (MeSH) Hirsutism Anatomical therapeutic chemical (ATC) code D11AX

### Pharmacotherapeutic group

Other dermatological preparations

### Therapeutic indication

Treatment of facial hirsutism in women.

## Authorisation details

EMA product number EMEA/H/C/000325 Marketing authorisation holder

Almirall, S.A.

Ronda General Mitre, 151

Marketing authorisation issued 19/03/2001 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vaniqa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (230.6 KB - PDF)

**First published:** 28/09/2009

**Last updated:** 27/11/2024

[View](/en/documents/procedural-steps-after/vaniqa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Vaniqa : EPAR - Procedural steps taken before authorisation

English (EN) (14.84 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/vaniqa-epar-procedural-steps-taken-authorisation_en.pdf)

Vaniqa : EPAR - Scientific Discussion

English (EN) (239.3 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/vaniqa-epar-scientific-discussion_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/11/2024

## Share this page

[Back to top](#main-content)